Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, ...

A survey of ENT clinicians reveals variability in managing chronic rhinosinusitis with nasal polyps, including steroid ...

A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges ...

U pstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic ...

Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe ...

PurposeThis review aims to explore the pathophysiological mechanisms and emerging therapies for type 2 chronic rhinosinusitis with nasal polyps (CRSwNP), dri ...

Background and purpose: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition marked by high recurrence and limited therapeutic efficacy. This study investigates the ...

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.